REG - Tristel PLC - Confirmation of CEO Transition, Directorate Change

TristelAnnouncement

02/09/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240902:nRSB3937Ca&default-theme=true

RNS Number : 3937C  Tristel PLC  02 September 2024

 

Tristel plc

("Tristel" or the "Company")

 

Confirmation of CEO Transition and Directorate Change

 

Tristel plc (AIM: TSTL), the manufacturer of infection prevention products,
confirms that Matt Sassone has today assumed his position of CEO of Tristel,
following Paul Swinney's retirement, as previously announced on 10 June 2024
(https://www.londonstockexchange.com/news-article/TSTL/appointment-of-ceo/16510247)
.

 

The Company also announces that Bart Leemans will step down from the Tristel
Board as an Executive Director. He will remain with the business and continue
to focus his efforts on the French market in his capacity as Managing
Director, Tristel SAS. There are no current plans to replace Bart on the
Tristel Board.

 

Bart was appointed in November 2018 following Tristel's acquisition of his
business, the Ecomed Group, the Company's then distributor in Belgium, the
Netherlands and France. The French market continues to represent significant
untapped growth potential for the Company; sales in France during the year
ended 30 June 2024 were £3.0 million, approximately 7% of the Group's total
of £41.9 million, compared with 13% of Group sales generated in Germany and
39% in the UK.

 

Bruno Holthof, Chair of Tristel, commented: "I would like to welcome Matt to
our Company, and also thank Bart for his contribution to the Board during his
tenure. He has brought with him great entrepreneurial spirit and drive and I
am pleased that he will continue to contribute to the growth of the business
through dedicating his efforts to the French market."

 

 

For further information please contact:

 

 Tristel plc                            Via Walbrook PR
 Matt Sassone, Chief Executive Officer  www.investors.tristel.com (http://www.investors.tristel.com/)
 Liz Dixon, Chief Financial Officer

 Walbrook PR Ltd                        Tel: 020 7933 8780 or tristel@walbrookpr.com
 Paul McManus                           Mob: 07980 541 893
 Charlotte Edgar                        Mob: 07884 664 686

 Cavendish Capital Markets Limited      Tel: 020 7220 0500
 Geoff Nash, Camilla Hume/Trisyia Jamaludin (Corporate Finance)
 Sunila de Silva (Corporate Broking)

 

The information contained within this announcement is deemed by the Company to
constitute inside information as stipulated under the Market Abuse Regulation
("MAR") EU no.596/2014. Upon the publication of this announcement via
Regulatory Information Service ("RIS"), this inside information is now
considered to be in the public domain.

 

About Tristel plc

Tristel plc is a global infection prevention company focussed on the
manufacture and supply of products using its unique proprietary chlorine
dioxide (ClO(2)) chemistry. The Company is a market leader in manual
decontamination of medical devices, supplying hospitals under the Tristel
(https://tristel.com/) brand, and under the Cache
(https://thecachecollection.com/) brand provides products for sporicidal
surface disinfection, in a format which is a sustainable alternative to
commonly used pre-wetted plastic wipes.

 

Tristel's head office and manufacturing facility is located in Snailwell, near
Cambridge, and operates globally employing approximately 250 people across 14
subsidiaries selling into 40 countries.

 

The Company has been listed on the London Stock Exchange's AIM market since
2005 (AIM: TSTL).

 

For more information about Tristel's product range please visit:
https://tristel.com (https://tristel.com) .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAURRNRSBUWOAR